NCT05207514 is a Phase 3 clinical trial of Nanoxel M in Breast Cancer, sponsored by Samyang Biopharmaceuticals Corporation.

Who is sponsoring NCT05207514?

NCT05207514 is sponsored by Samyang Biopharmaceuticals Corporation.

What drugs are being tested in NCT05207514?

Interventions in NCT05207514: Nanoxel M, Taxotere, Doxorubicin, Cyclophosphamide.

What condition does NCT05207514 study?

NCT05207514 studies Breast Cancer.

Is NCT05207514 still recruiting?

NCT05207514 is currently terminated. Last updated 17 May 2024.

Last reviewed 2024-05-17 · How we verify

NCT05207514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Terminated Phase 3 Last updated 17 May 2024

What this trial tests

Phase 3 trial testing Nanoxel M in Breast Cancer in 26 participants. Terminated before completion.

Timeline

31 March 2022

Primary endpoint
7 February 2024

9 May 2024

Quick facts

Lead sponsor	Samyang Biopharmaceuticals Corporation
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	31 March 2022
Primary completion	7 February 2024
Estimated completion	9 May 2024
Sites	1 location across South Korea

Drugs / interventions tested

Nanoxel M — full drug profile →
Taxotere (Docetaxel) — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Samyang Biopharmaceuticals Corporation — full company profile →

Who can join

19 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Polymeric Nanoparticles for Drug Delivery.
Beach MA, Nayanathara U, Gao Y, Zhang C, et al · · 2024 · cited 476× · PMID 38626459 · DOI 10.1021/acs.chemrev.3c00705
Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials.
Serras A, Faustino C, Pinheiro L. · · 2024 · cited 4× · PMID 39204392 · DOI 10.3390/pharmaceutics16081047
Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems
Bryaskova R, Staykov K, Ganchev D. · · 2026

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Samyang Biopharmaceuticals Corporation trials

Trials by the same sponsor.

NCT07467239 — A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds · NA · recruiting
NCT06961448 — A Study in Adults Evaluating Polycaprolactone Microsphere Filler for Treatment of Moderate to Severe Nasolabial Folds · NA · not yet recruiting
NCT06402058 — A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement · NA · not yet recruiting
NCT06295172 — A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement · NA · not yet recruiting
NCT06093321 — A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05207514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samyang Biopharmaceuticals Corporation
Last refreshed: 17 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing